Hims & Hers Health disclosed a transaction with the SEC, while Director David Wells acquired stock and TD Cowen covered the stock.

The entities involved

• Hims & Hers Health →

  American telehealth company

  Nothing else this week.

• SEC →

  Slovak company

  • DHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Mon 17:57
  • The Fidelis Partnership is incorporating in Bermuda and filing for an initial public offering on the NYSE, with principal offices in London and a main office in Dublin.Mon 17:12
• TD Cowen →

  American investment bank

  • Analyst downgraded Ag Growth International Inc. due to debt management risks.Mon 12:33
  • TD Cowen raised its price target and gave a buy rating for Travere Therapeutics, Inc., while various institutional investors bought into the company.Mon 10:36

Related events

• TD Cowen provided analyst ratings and price targets for Ardelyx, accompanied by required stock transaction filings with the SEC.Aug 26
• HCW Biologics Inc. filed disclosures with the SEC and its shares are listed on Nasdaq.Jun 27
• Clover Health Investments disclosed executive stock sales via a filing with the SEC on September 14, 2026.Sep 15
• Pharvaris N.V. filed disclosures with the SEC, and its president sold company stock.Sep 9
• Gen Digital disclosed a director stock sale in an SEC filing.Aug 26